对于多发性骨髓瘤患者，在自体移植前进行诱导化疗时，环磷酰胺、沙利度胺和地塞米松联合用药是环磷酰胺-长春新碱-阿霉素-甲泼尼龙的一种有效替代方案：一项病例匹配分析。
The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis.
作者信息
Wu Ping, Davies Faith E, Horton Clive, Jenner Matthew W, Krishnan Biju, Alvares Caroline L, Saso Radovan, McCormack Rita, Dines Sharon, Treleaven Jennifer G, Potter Michael N, Ethell Mark E, Morgan Gareth J
机构信息
Haemato-Oncology Unit, Royal Marsden Hosptial, Sutton, Surrey, UK.
出版信息
Leuk Lymphoma. 2006 Nov;47(11):2335-8. doi: 10.1080/10428190600821955.
A retrospective case-matched study was conducted to compare the oral regimen CTD (cyclophosphamide - thalidomide - dexamethasone) and infusional CVAMP (cyclophosphamide - vincristine - doxorubicin - methylprednisolone) as induction therapy followed by autologous peripheral blood stem-cell transplantation (PBSCT) for newly diagnosed multiple myeloma patients. The response rate after three cycles of treatment was statistically higher with CTD (n = 27) compared to CVAMP (n = 27) (89% vs. 56%, P = 0.016). Toxicity studies showed more neutropenia (grade 3/4) (4% vs. 60%, P = 0.0002) with CVAMP and more thrombotic episodes with CTD (11% vs. 4%). CTD may emerge as the superior induction regimen prior to PBSCT, in terms of high efficacy and better tolerability.
开展了一项回顾性病例匹配研究，以比较口服方案CTD（环磷酰胺-沙利度胺-地塞米松）和静脉输注方案CVAMP（环磷酰胺-长春新碱-阿霉素-甲基泼尼松龙）作为新诊断的多发性骨髓瘤患者的诱导治疗方案，并随后进行自体外周血干细胞移植（PBSCT）。与CVAMP组（n = 27）相比，CTD组（n = 27）在三个治疗周期后的缓解率在统计学上更高（89% 对56%，P = 0.016）。毒性研究显示，CVAMP组有更多的中性粒细胞减少（3/4级）（4% 对60%，P = 0.0002），而CTD组有更多的血栓形成事件（11% 对4%）。就高疗效和更好的耐受性而言，CTD可能成为PBSCT前更优的诱导方案。
Zotero 插件